Invesco Ltd. Allogene Therapeutics, Inc. Transaction History
Invesco Ltd.
- $499 Billion
- Q3 2024
A detailed history of Invesco Ltd. transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Invesco Ltd. holds 119,127 shares of ALLO stock, worth $176,307. This represents 0.0% of its overall portfolio holdings.
Number of Shares
119,127
Previous 120,138
0.84%
Holding current value
$176,307
Previous $279,000
19.35%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding ALLO
# of Institutions
166Shares Held
133MCall Options Held
59.4KPut Options Held
113K-
Tpg Gp A, LLC Fort Worth, TX18.7MShares$27.7 Million1.25% of portfolio
-
Black Rock Inc. New York, NY16.4MShares$24.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8MShares$11.8 Million0.0% of portfolio
-
State Street Corp Boston, MA7.01MShares$10.4 Million0.0% of portfolio
-
Capital World Investors Los Angeles, CA6.9MShares$10.2 Million0.0% of portfolio
About Allogene Therapeutics, Inc.
- Ticker ALLO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 143,807,008
- Market Cap $213M
- Description
- Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...